Leerink Partnrs Issues Optimistic Outlook for STOK Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities researchers at Leerink Partnrs raised their FY2029 earnings per share estimates for Stoke Therapeutics in a report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of $0.60 per share for the year, up from their prior estimate of $0.55. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.38. The company had revenue of $22.61 million for the quarter, compared to analysts’ expectations of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

A number of other brokerages have also weighed in on STOK. Chardan Capital reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 19th. HC Wainwright restated a “buy” rating and issued a $47.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $24.67.

Stoke Therapeutics Stock Up 1.7 %

Shares of NASDAQ:STOK opened at $7.69 on Wednesday. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $17.58. The firm’s 50-day simple moving average is $7.95 and its 200-day simple moving average is $10.41. The company has a market cap of $415.86 million, a price-to-earnings ratio of -3.66 and a beta of 1.09.

Insider Buying and Selling

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the transaction, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. This trade represents a 6.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Barry Ticho sold 3,884 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the sale, the insider now directly owns 63,962 shares in the company, valued at $554,550.54. This trade represents a 5.72 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,532 shares of company stock valued at $143,332. 11.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Toronto Dominion Bank purchased a new stake in shares of Stoke Therapeutics in the fourth quarter valued at $35,001,000. RTW Investments LP lifted its holdings in Stoke Therapeutics by 10.1% in the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock valued at $56,512,000 after purchasing an additional 471,240 shares in the last quarter. Norges Bank purchased a new position in Stoke Therapeutics in the 4th quarter valued at about $3,472,000. Tang Capital Management LLC acquired a new stake in shares of Stoke Therapeutics during the 4th quarter worth about $3,309,000. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in shares of Stoke Therapeutics during the fourth quarter worth about $3,218,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.